Table 1.
Patient characteristics
| Factor | Enrolled (n = 69) | Eligible (n = 66) | ||||
|---|---|---|---|---|---|---|
| Arm C | Arm S | Total | Arm C | Arm S | Total | |
| Sex | ||||||
| Female | 18 | 18 | 36 | 17 | 18 | 35 |
| Male | 16 | 17 | 33 | 15 | 16 | 31 |
| Age (years) | ||||||
| Median | 53 | 50 | 52 | 54.5 | 49.5 | 52.5 |
| Range | 36–65 | 26–69 | 26–69 | 36–65 | 26–69 | 26–69 |
| Performance status (ECOG) | ||||||
| 0 | 29 | 30 | 59 | 28 | 29 | 57 |
| 1 | 5 | 5 | 10 | 4 | 5 | 9 |
| Histopathology (REAL) † | ||||||
| Follicular, grade 1 | 12 | 11 | 23 | 11 | 11 | 22 |
| Follicular, grade 2 | 21 | 19 | 40 | 20 | 19 | 39 |
| Follicular, grade 3 | 0 | 2 | 2 | 0 | 2 | 2 |
| Marginal zone B‐cell | 1 | 0 | 1 | 1 | 0 | 1 |
| Low grade B‐NHL, NOS ‡ | 0 | 2 | 2 | 0 | 2 | 2 |
| No specimen submitted§ | 0 | 1 | 1 | 0 | 0 | 0 |
| Clinical stage (Ann Arbor) | ||||||
| III | 14 | 15 | 29 | 13 | 14 | 27 |
| IV | 20 | 20 | 40 | 19 | 20 | 39 |
| B‐symptoms | ||||||
| Absent | 30 | 33 | 63 | 29 | 32 | 61 |
| Present | 4 | 2 | 6 | 3 | 2 | 5 |
| LDH | ||||||
| Normal | 32 | 31 | 63 | 31 | 30 | 61 |
| Elevated | 2 | 4 | 6 | 1 | 4 | 5 |
| No. of extranodal sites | ||||||
| 0–1 | 25 | 26 | 51 | 24 | 25 | 49 |
| ≤2 | 9 | 9 | 18 | 8 | 9 | 17 |
| International Prognostic Index | ||||||
| Low | 21 | 21 | 42 | 21 | 20 | 41 |
| Low‐intermediate | 12 | 12 | 24 | 10 | 12 | 22 |
| High‐intermediate | 1 | 1 | 2 | 1 | 1 | 2 |
| High | 0 | 1 | 1 | 0 | 1 | 1 |
| Follicular Lymphoma International Prognostic Index | ||||||
| Low | 16 | 15 | 31 | 16 | 15 | 31 |
| Intermediate | 12 | 15 | 27 | 10 | 14 | 25 |
| High | 6 | 5 | 11 | 5 | 5 | 10 |
†
According to the diagnosis by the central pathology review.
‡
Low‐grade B‐cell non‐Hodgkin lymphoma (NHL) not otherwise specified. ‡Specimen was not submitted to the central pathology review. LDH, lactic dehydrogenase.